SEC Comment Letter 0000000000-23-012560 to Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc.
Date: Nov. 16, 2023 · CIK: 0000890821 · Accession: 0000000000-23-012560
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275380
Letter
United States securities and exchange commission logo November 16, 2023 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 Re:Enveric Biosciences, Inc. Registration Statement on Form S-1 Filed November 8, 2023 File No. 333-275380 Dear Joseph Tucker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brad Wyatt
Show Raw Text
United States securities and exchange commission logo
November 16, 2023
Joseph Tucker
Chief Executive Officer
Enveric Biosciences, Inc.
4851 Tamiami Trail N, Suite 200
Naples, FL 34103
Re:Enveric Biosciences, Inc.
Registration Statement on Form S-1
Filed November 8, 2023
File No. 333-275380
Dear Joseph Tucker:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brad Wyatt